WO2006112276A1 - プロポフォール含有脂肪乳剤 - Google Patents
プロポフォール含有脂肪乳剤 Download PDFInfo
- Publication number
- WO2006112276A1 WO2006112276A1 PCT/JP2006/307450 JP2006307450W WO2006112276A1 WO 2006112276 A1 WO2006112276 A1 WO 2006112276A1 JP 2006307450 W JP2006307450 W JP 2006307450W WO 2006112276 A1 WO2006112276 A1 WO 2006112276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fat emulsion
- provophor
- oil
- emulsifier
- emulsion
- Prior art date
Links
- 239000002960 lipid emulsion Substances 0.000 title claims abstract description 86
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title abstract description 18
- 229960004134 propofol Drugs 0.000 title abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 30
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 28
- 206010047095 Vascular pain Diseases 0.000 claims description 32
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003549 soybean oil Substances 0.000 claims description 9
- 235000012424 soybean oil Nutrition 0.000 claims description 9
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 150000003904 phospholipids Chemical class 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940042880 natural phospholipid Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000839 emulsion Substances 0.000 abstract description 23
- 238000000034 method Methods 0.000 abstract description 10
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004194 lidocaine Drugs 0.000 abstract description 7
- 239000003589 local anesthetic agent Substances 0.000 abstract description 6
- 229960005015 local anesthetics Drugs 0.000 abstract 1
- 239000000306 component Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 20
- 238000004945 emulsification Methods 0.000 description 18
- 238000002156 mixing Methods 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- -1 polyoxyethylene Polymers 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000001603 reducing effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 150000004671 saturated fatty acids Chemical class 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940072271 diprivan Drugs 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100025273 Monocarboxylate transporter 5 Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 108091006600 SLC16A4 Proteins 0.000 description 1
- 108091006602 SLC16A5 Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- the present invention relates to a propofol-containing fat emulsion that significantly reduces vascular pain upon administration by intravenous injection or infusion.
- Provophor (2,6-diisopropylphenol) is a fat-soluble substance having hypnotic properties. Since the provophor is hardly soluble in water, it is generally prepared in the form of an oil-in-water fat emulsion that can be administered directly into the blood by intravenous injection or infusion using an oily component and an emulsifier. Yes.
- the fat emulsion is widely used as a general anesthetic, sedative and the like (see, for example, US Pat. No. 5,714,520).
- these proposed preparations are preparations in the form of an aqueous solution (or a lyophilized product thereof) that does not contain an oily component as compared with fat emulsions.
- aqueous solution preparation instead of fat emulsion.
- fat emulsions There is no mention of fat emulsions that have been prevented or reduced.
- the proposed formulation is a fat-soluble substance that is almost insoluble in water, and is at least equimolar with respect to the propofol for solubilization of propofol (about 3-80 w / v in the whole aqueous solution).
- Patent Document 1 Japanese Patent Laid-Open No. 2002-179562
- Patent Document 2 European Patent Application Publication No. 02/074200 (US Patent Application Publication No. 2003-73665)
- Patent Document 3 European Patent Application Publication No. 03/063824
- Non-Patent Document 1 W. Klemment, J. O. Arndt: British Journal of Anaesthesia, 1991; 67: 281-284
- Non-Patent Document 2 EEM Lilley, et al "Anaesthesia, 1996; 51: 815-818 Disclosure of the invention
- the main object of the present invention is to reduce vascular pain at the time of administration without blending a local anesthetic such as lidocaine, and it is excellent without blending an emulsion stabilizer or a solubilizer. It would be desirable to provide an improved provophor-containing fat emulsion having good emulsion stability.
- the present invention provides the following fat emulsion and method for producing the same.
- Item 1 Provophor-containing fat emulsion with reduced vascular pain when administered intravenously or intravenously, comprising Provophor 0.1-2 w / v%, oily component 10-20 w / v% and emulsifier 2-5 w / v %,
- the blending ratio of the oil component to Provophor is in the range of about 5 to 200 times by weight
- the blending ratio of the emulsifier to Provophor is in the range of about 0.9 to 50 times by weight
- the average particle size of the emulsified particles is Fat emulsion that is 180 nm or less.
- Item 2 The above-mentioned item wherein the oil component is at least one selected from the group power consisting of natural triglycerides and synthetic triglycerides, and the emulsifier is at least one selected from the group power also including natural phospholipids and synthetic phospholipid power
- the oil component is at least one selected from the group power consisting of natural triglycerides and synthetic triglycerides
- the emulsifier is at least one selected from the group power also including natural phospholipids and synthetic phospholipid power
- Item 3 The fat emulsion according to Item 2, wherein the oil component is soybean oil and the emulsifier is egg yolk lecithin.
- Item 4 The fat emulsion according to Item 1, comprising 0.5-2 w / v% propofol, 10-20 w / v% oily component, and 2-5 w / v% emulsifier.
- Item 5 The method for producing a fat emulsion according to Item 1, comprising emulsifying a mixture containing provophor, an oil component and an emulsifier in water.
- the present invention combines provophor, an oil component and an emulsifier in a predetermined ratio.
- the resulting emulsion is excellent in emulsion stability, and the strength of this type of administration is such that this type of provophor-containing fat emulsion cannot be avoided. It was completed on the basis of the discovery of the fact that there are few or no serious side effects, sometimes accompanied by vascular pain.
- the fat emulsion of the present invention has the following advantages.
- Provophor (2,6-diisopropylphenol) is a compound that is known to be usable as a general anesthetic, a sedative and the like in the pharmaceutical field as described in Patent Document 1, for example. Provophor hardly dissolves in water, and it is difficult to prepare an aqueous solution containing an effective dose thereof.
- the total amount is about 0.1-2 w / v%, preferably about 0.5-2 w / v% (concentration) of the total fat emulsion.
- w / v% used for the blending amount (concentration) of each component constituting the fat emulsion of the present invention is “weight of each component (g) / total fat emulsion”.
- the oily component for example, vegetable oil (natural tridalylide) can be used.
- vegetable oil naturally tridalylide
- specific examples thereof include soybean oil, cottonseed oil, rapeseed oil, sesame oil, safflower oil, corn oil, peanut oil, olive oil, coconut oil, perilla oil, castor oil and the like. Of these, soybean oil is preferred.
- the oily component may be a medium chain triglyceride (MCT) such as 2-linoleoyl-1,3-dioctanol glycerol, which may be a chemically synthesized triglyceride, such as 8-10 carbon atoms. It may be a triglyceride.
- MCT medium chain triglyceride
- Commercial products mainly composed of strong medium-chain triglycerides (MCT) include trade name: “COCONARD” (COCONARD, Kao), trade name: “ODO” (Nisshin Oil Industries), trade name: “Miglyol (Myglyol, SASOL) and trade name: “Panasate” (Panasate, Nippon Oil & Fats).
- the oil component may be animal oil, mineral oil, synthetic oil, essential oil or the like, not limited to the above vegetable oils and medium chain triglycerides.
- One of them can be used alone, or two or more of them can be used in combination. When two or more types are used in combination, it is possible to select different group strengths for each component to be used together without needing to select the same group strength such as vegetable oil, medium chain triglyceride, animal oil, or mineral oil.
- the amount of the oil component is in the range of 10-20 w / v% in the fat emulsion of the present invention.
- the amount of the oily component is in the range of about 5 to 200 times the weight of Provophor in the fat emulsion of the present invention.
- this blending amount (blending ratio relative to provophor) is below the above range, the concentration of provophor in the aqueous phase, which is the cause of vascular pain, increases, and the desired vascular pain reducing effect cannot be obtained.
- the vascular pain alleviation effect can be achieved, but the formulation itself has a risk of causing hyperlipidemia by its administration. Therefore, it is not so preferable.
- the emulsifiers typically include yolk lecithin, egg yolk phosphatidylcholine, soy lecithin, soy phosphatidylcholine, hydrogenated egg yolk lecithin, hydrogenated egg yolk phosphatidylcholine, hydrogenated soy lecithin, water, which are natural phospholipids. And soy phosphatidylcholine.
- the emulsifier may be a chemically synthesized phospholipid.
- Chemically synthesized phospholipids include phosphatidylcholine (dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine), phosphatidylglycerol (dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylphosphatidylphosphatidylcholine).
- phosphatidylcholine dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleoylphosphatidylcholine
- phosphatidylglycerol dipalmitoylphosphatidylglycerol, dimyristoylphosphatidylglycerol, distearoylphosphatidylphosphatidyl
- phosphatidylethanolamine dipalmitoyl phosphatidylethanolamine, dimyristoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, dioleoylphosphatidylethanolamine, etc. Is included.
- emulsifiers can be used singly or in combination of two or more.
- preferable emulsifiers include egg yolk lecithin, egg yolk phosphatidylcholine, soybean lecithin and soybean phosphatidylcholine.
- egg yolk lecithin is preferred.
- the blending amount of the emulsifier in the fat emulsion of the present invention is in the range of 2-5 w / v%.
- the blending amount of the emulsifier is selected at a ratio of about 0.9 to 50 times the weight of Provophor.
- a fat emulsion having an excellent vascular pain reducing effect can be obtained within the range of the blending amount and ratio.
- the value is below the lower limit, there is a disadvantage that it is difficult to achieve the desired effect of reducing vascular pain in the present invention.
- the propofol-containing fat emulsion of the present invention may be further blended with appropriate amounts of various additives known to be blended in this type of fat emulsion if desired, although it is not particularly necessary.
- the additive include an antioxidant, an antibacterial agent, a pH adjuster, and an isotonic agent.
- antioxidants include sodium metabisulfite (Also acting as an antibacterial agent), sodium sulfite, sodium bisulfite, potassium metabisulfite, potassium sulfite, sodium thiosulfate and the like.
- Antibacterial agents include, for example, strength sodium prillate, methyl benzoate, sodium metabisulfite (which also acts as an anti-oxidant agent), sodium edetate, and the like.
- pH adjusters examples include hydrochloric acid, acetic acid, lactic acid, malic acid, citrate, and sodium hydroxide.
- the tonicity agent glycerin; sugars such as glucose, fructose and maltose; sugar alcohols such as sorbitol and xylitol can be used.
- the oil-soluble material can be used by being mixed in advance with the oil-based component constituting the fat emulsion.
- the water-soluble material can be premixed in the water for injection used in the preparation of the fat emulsion, or added to the resulting fat emulsion and dissolved in the aqueous phase. The amount of these additives is obvious to those skilled in the art and is not particularly different from those conventionally known.
- a stabilizer for improving emulsification stability can be added to the provophor-containing fat emulsion of the present invention, if desired.
- the stabilizer includes a normal surfactant and the like.
- these surfactants the following substances (a) to (c), which the present inventors have newly found a stable effect on this type of fat emulsion, are included (International Publication No. 1). 2004/052354 pamphlet). The description of this document (WO 2004/052354 pamphlet) is incorporated herein by reference.
- Fatty acid strength obtained by esterifying the glycerol moiety is a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms, preferably a straight chain having 12 to 18 carbon atoms.
- phosphatidylethanolamine modified with polyalkylene glycol wherein the fatty acid is a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms, esterified in the glycerol moiety,
- at least one phospholipid derivative which is a linear or branched saturated or unsaturated fatty acid having 14 to 18 carbon atoms,
- a linear or branched saturated or unsaturated fatty acid having 10 to 22 carbon atoms preferably a linear or branched saturated or unsaturated fatty acid having 10 to 20 carbon atoms At least one selected from the group.
- the fat emulsion of the present invention can be prepared by adding a predetermined amount of the above-mentioned provophor, oil component, emulsifier and additives to be added if necessary to water and emulsifying the mixture.
- the addition mixing and emulsification method of each component is not particularly limited as long as an emulsion is obtained, and can be carried out according to a general method.
- the fat emulsion of the present invention can be obtained by a method of emulsifying the mixture after adding provophor, an oil component and an emulsifier in water.
- a means for emulsifying the mixture employed in the emulsification dispersion method for example, rough emulsification using a homomixer such as TK homomixer manufactured by Tokushu Kagaku Kogyo Co., Ltd. usually requires 5 minutes or more at 5000 rpm or more.
- a fine emulsification means using a high-pressure homogenizer and an ultrasonic homogenizer can generally be carried out by passing it about 2-50 times, preferably about 5-20 times under a pressure condition of about 200 kg / cm 2 or more. Each emulsification operation may be carried out by employing a slight heating operation (usually about 55-80 ° C) that may be carried out at room temperature.
- the fat emulsion of the present invention is prepared so that the average particle size of the emulsified particles is 180 ° or less by the above-described emulsification and dispersion method.
- the average particle size of the emulsified particles is 180 ° or less, the occurrence of vascular pain during administration of the fat emulsion can be remarkably reduced. Pain relief effect is not fully expressed.
- the obtained fat emulsion of the present invention can be adjusted to a desired value if necessary, and then filtered and sterilized to obtain a product according to a conventional method.
- the pH of the provophor-containing fat emulsion product of the present invention can usually be adjusted to about 5.0 to 9.0, preferably about 6.0 to 8.0.
- Filtration can be performed using a conventional membrane filter. Sterilization can be performed by, for example, high-pressure steam sterilization, hot water immersion sterilization, shower sterilization, or the like.
- the fat emulsion of the present invention has excellent emulsification stability, particularly emulsification stability against temperature changes. That is, the fat emulsion of the present invention has the following excellent characteristics.
- the average particle size of the fat particles constituting the fat emulsion of the present invention is as fine as about 180 ° or less, and the particle size does not substantially change before and after sterilization.
- the fat emulsion of the present invention not only maintains excellent emulsification stability for a long period of time, but also the activity of Provophor as an active ingredient hardly decreases even by heat sterilization operation or subsequent long-term storage.
- the inventors of the present invention have confirmed that the activity of this provophor does not substantially decrease even when the fat emulsion of the present invention is stored at 60 ° C. for 1 month, for example.
- the fat emulsion of the present invention has the effect of remarkably reducing the occurrence of vascular pain at the time of administration based on the use of a predetermined amount of each of provophor, oil component and emulsifier. In addition, it has excellent emulsification stability and safety, and can be safely applied to patients who are expected to have a medicinal effect of propofol.
- the average particle size of the emulsified particles (fat particles) in the fat emulsions obtained in the examples was measured by a dynamic light scattering method.
- the average particle diameter of the emulsified particles in the present specification is a value measured by this method.
- the fat emulsion of the present invention (total amount lOOmL) comprising the components shown in Table 1 below was prepared as follows. The numerical value of each component in Table 1 is the concentration (w / v%) in the resulting fat emulsion.
- MCT Tetracerides having 8 to 10 carbon atoms: Trade name: “Miglyol” (Myglyol, SASOL)) First, among the components listed in Table 1, Provophor and oily components soybean oil and MC
- T was mixed, and egg yolk lecithin was added to the resulting mixture, and then a solution in which an amount of glycerin having a final concentration of 2.21 w / v% was dissolved in water for injection was prepared.
- This mixture was roughly emulsified using a POLYTRON homogenizer (trade name) (KINEMATICA) under nitrogen flow and heating at 25,000 rpm for 10 minutes.
- the emulsified liquid was emulsified at 40-80 ° C, and the emulsified pressure was 550 kg / cm 2 in a nitrogen stream until the average particle size became 180 nm or less.
- AAV high-pressure homogenizer
- the fat emulsion sample of the present invention obtained by force is excellent in emulsion stability in which the particle diameter does not change even after high-pressure steam sterilization in the pH range of 7 to 8, and the average particle size of the emulsion particles The diameters were all 180 nm or less and were finely balanced.
- a fat emulsion sample of Comparative Example 2 was prepared in the same manner as in Example 1, except that the blending amount of egg yolk lecithin was 1.2%.
- a fat emulsion sample of Comparative Example 3 was prepared in the same manner as in Example 2, except that the number of fine emulsifications was changed so that the average particle diameter of the obtained emulsified particles became a predetermined value.
- Table 1 below shows the composition, average particle diameter (nm), and electromyogram area ratio (%) of each sample obtained in each of the above examples.
- the electromyogram area ratio (%) in Table 1 can accurately evaluate vascular pain that may occur when each fat emulsion sample is administered to the human body. Required by animal testing.
- Fat emulsion samples were administered to the rat femoral artery, and the degree of vascular pain was evaluated by measuring the electromyogram near the administration vessel.
- the fact that vascular pain can be accurately evaluated by measuring an electromyogram according to this method is, for example, as described in the following literature.
- Literature name R. Ando, A. onezawa, C. Watanabe and S. Kawamura. An assessment of vascular pain using the flexor reflex in anesthetized rats. Methods rind Exp Clin P harmacol, 2004 Mar; 26 (2): 109—15
- 0.05 mL of 1% diprivan injection (trade name) is administered from the indwelling polyethylene catheter, and electromyogram measurement is performed after administration. The area under the peak in the figure was calculated (this value is the reference value).
- each of the rats in each group was prepared according to the inventive fat emulsion sample prepared in Example 1-3 (adjusted to PH8) and Comparative Example 1-3. Comparison Each 0.05 mL of the fat emulsion sample (adjusted to PH8) was administered, and after administration, the area under the peak of the electromyogram was calculated in the same manner.
- index obtained by this test can exclude individual differences in pain sensitivity. If this index is 100% or less, it means that vascular pain is reduced compared to 1% Diprivan injection. In addition, the smaller the value (electromyogram area ratio), the greater the effect of reducing vascular pain.
- the provophor fat emulsion of the present invention is excellent in safety without impairing emulsification stability, and also prevents or reduces pain during administration, such as general anesthetics and sedatives. It is useful as a pharmaceutical product.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06731397A EP1875901A4 (en) | 2005-04-13 | 2006-04-07 | PROPOFOL CONTAINING FAT EMULSION |
US11/910,419 US20090069445A1 (en) | 2005-04-13 | 2006-04-07 | Propofol-containing fat emulsions |
JP2007521182A JPWO2006112276A1 (ja) | 2005-04-13 | 2006-04-07 | プロポフォール含有脂肪乳剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005115487 | 2005-04-13 | ||
JP2005-115487 | 2005-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006112276A1 true WO2006112276A1 (ja) | 2006-10-26 |
Family
ID=37115002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/307450 WO2006112276A1 (ja) | 2005-04-13 | 2006-04-07 | プロポフォール含有脂肪乳剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090069445A1 (ja) |
EP (1) | EP1875901A4 (ja) |
JP (1) | JPWO2006112276A1 (ja) |
KR (1) | KR20080003860A (ja) |
CN (1) | CN101155580A (ja) |
TW (1) | TW200722075A (ja) |
WO (1) | WO2006112276A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011145660A1 (ja) * | 2010-05-21 | 2011-11-24 | 富士フイルム株式会社 | プロポフォール含有水中油型エマルション組成物 |
CN103301062A (zh) * | 2013-06-03 | 2013-09-18 | 四川百利药业有限责任公司 | 一种中长链脂肪乳注射液的制备方法 |
WO2016047664A1 (ja) * | 2014-09-25 | 2016-03-31 | 富士フイルム株式会社 | プロポフォール含有水中油型エマルション組成物及びその製造方法 |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009003980A1 (de) | 2009-01-07 | 2010-07-08 | B. Braun Melsungen Ag | Propofol in triheptanoinhaltiger Trägeremulsion |
RU2012144777A (ru) * | 2010-05-13 | 2014-06-20 | Астразенека Аб | Инъекционная эмульсия седативного снотворного агента |
CN104288130A (zh) * | 2013-07-16 | 2015-01-21 | 天津迈迪瑞康生物医药科技有限公司 | 一种注射用丙泊酚组合物、其制备方法及用途 |
US11219606B2 (en) * | 2013-10-11 | 2022-01-11 | University Of Florida Research Foundation, Inc. | Method of manufacturing stable emulsions and compositions containing the same |
CN104739764B (zh) * | 2013-12-31 | 2017-10-27 | 四川科伦药业股份有限公司 | 一种脂肪乳注射液及其制备方法 |
CN115252550A (zh) * | 2022-07-27 | 2022-11-01 | 郭晓光 | 一种异丙酚口服麻醉药及其ph值调节方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565220A (ja) * | 1991-04-28 | 1993-03-19 | Green Cross Corp:The | 輸液製剤 |
JPH06312923A (ja) * | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | 末梢静脈投与用栄養輸液 |
JPH09508413A (ja) * | 1994-02-04 | 1997-08-26 | スコーツイア・リピツドテクニク・アクチエボラーグ | 水中油エマルジョン |
JP2002179562A (ja) | 2000-12-14 | 2002-06-26 | Towa Yakuhin Kk | 安定な静注用無痛プロポフォール脂肪乳剤 |
WO2002074200A1 (en) | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
JP2003502363A (ja) * | 1999-06-21 | 2003-01-21 | コンイル ファーマシューティカル カンパニー、リミテッド | プロポフォールを含有する静脈内注射用麻酔剤組成物 |
US20030073665A1 (en) | 2001-03-20 | 2003-04-17 | Thompson Diane O. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
WO2003063824A2 (en) | 2002-02-01 | 2003-08-07 | Shimoda Biotech (Pty) Ltd | Pharmaceutical composition |
JP2003535884A (ja) * | 2000-06-16 | 2003-12-02 | スカイファーマ・カナダ・インコーポレーテッド | プロポフォールの改善された注射可能な分散物 |
WO2004052354A1 (ja) | 2002-12-06 | 2004-06-24 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
WO2005067905A1 (ja) * | 2004-01-14 | 2005-07-28 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6028108A (en) * | 1998-10-22 | 2000-02-22 | America Home Products Corporation | Propofol composition comprising pentetate |
-
2006
- 2006-04-07 WO PCT/JP2006/307450 patent/WO2006112276A1/ja active Application Filing
- 2006-04-07 EP EP06731397A patent/EP1875901A4/en not_active Withdrawn
- 2006-04-07 KR KR1020077025488A patent/KR20080003860A/ko not_active Application Discontinuation
- 2006-04-07 CN CNA2006800118789A patent/CN101155580A/zh active Pending
- 2006-04-07 US US11/910,419 patent/US20090069445A1/en not_active Abandoned
- 2006-04-07 JP JP2007521182A patent/JPWO2006112276A1/ja active Pending
- 2006-04-12 TW TW095112981A patent/TW200722075A/zh unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0565220A (ja) * | 1991-04-28 | 1993-03-19 | Green Cross Corp:The | 輸液製剤 |
JPH06312923A (ja) * | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | 末梢静脈投与用栄養輸液 |
JPH09508413A (ja) * | 1994-02-04 | 1997-08-26 | スコーツイア・リピツドテクニク・アクチエボラーグ | 水中油エマルジョン |
JP2003502363A (ja) * | 1999-06-21 | 2003-01-21 | コンイル ファーマシューティカル カンパニー、リミテッド | プロポフォールを含有する静脈内注射用麻酔剤組成物 |
JP2003535884A (ja) * | 2000-06-16 | 2003-12-02 | スカイファーマ・カナダ・インコーポレーテッド | プロポフォールの改善された注射可能な分散物 |
JP2002179562A (ja) | 2000-12-14 | 2002-06-26 | Towa Yakuhin Kk | 安定な静注用無痛プロポフォール脂肪乳剤 |
WO2002074200A1 (en) | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
US20030073665A1 (en) | 2001-03-20 | 2003-04-17 | Thompson Diane O. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
WO2003063824A2 (en) | 2002-02-01 | 2003-08-07 | Shimoda Biotech (Pty) Ltd | Pharmaceutical composition |
WO2004052354A1 (ja) | 2002-12-06 | 2004-06-24 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
WO2005067905A1 (ja) * | 2004-01-14 | 2005-07-28 | Otsuka Pharmaceutical Factory, Inc. | プロポフォール含有脂肪乳剤 |
EP1704858A1 (en) | 2004-01-14 | 2006-09-27 | Otsuka Pharmaceutical Factory, Inc. | Propofol-containing fat emulsion preparation |
Non-Patent Citations (3)
Title |
---|
E.E.M. LILLEY ET AL., ANAESTHESIA, vol. 51, 1996, pages 815 - 818 |
See also references of EP1875901A4 |
W. KLEMMENT; J.O. ARNDT, BRITISH JOURNAL OF ANAESTHESIA, vol. 67, 1991, pages 281 - 284 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011145660A1 (ja) * | 2010-05-21 | 2011-11-24 | 富士フイルム株式会社 | プロポフォール含有水中油型エマルション組成物 |
JP2012006898A (ja) * | 2010-05-21 | 2012-01-12 | Fujifilm Corp | プロポフォール含有水中油型エマルション組成物 |
CN103301062A (zh) * | 2013-06-03 | 2013-09-18 | 四川百利药业有限责任公司 | 一种中长链脂肪乳注射液的制备方法 |
WO2016047664A1 (ja) * | 2014-09-25 | 2016-03-31 | 富士フイルム株式会社 | プロポフォール含有水中油型エマルション組成物及びその製造方法 |
JPWO2016047664A1 (ja) * | 2014-09-25 | 2017-06-22 | 富士フイルム株式会社 | プロポフォール含有水中油型エマルション組成物及びその製造方法 |
US11992483B2 (en) | 2021-03-31 | 2024-05-28 | Cali Biosciences Us, Llc | Emulsions for local anesthetics |
Also Published As
Publication number | Publication date |
---|---|
TW200722075A (en) | 2007-06-16 |
KR20080003860A (ko) | 2008-01-08 |
US20090069445A1 (en) | 2009-03-12 |
EP1875901A1 (en) | 2008-01-09 |
EP1875901A4 (en) | 2008-06-04 |
CN101155580A (zh) | 2008-04-02 |
JPWO2006112276A1 (ja) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006112276A1 (ja) | プロポフォール含有脂肪乳剤 | |
KR102027613B1 (ko) | 호르몬 함유 유화액 | |
WO2005067905A1 (ja) | プロポフォール含有脂肪乳剤 | |
JP2019196398A (ja) | アプレピタントのエマルジョン製剤 | |
KR101391020B1 (ko) | 수난용성 약제를 함유한 약학 조성물 | |
IL153457A (en) | Improved injectable dispersions of propofol | |
JPS59216820A (ja) | プロスタグランジン脂肪乳剤 | |
US5635536A (en) | Emulsion suitable for administering a sphingolipid | |
JP2005225818A (ja) | パクリタキセル又はドセタキセルの医薬組成物 | |
JP2019510048A (ja) | 週1回又は隔週1回の投与に適したリラグルチドの粘弾性ゲル | |
KR101680163B1 (ko) | 프로스타글란딘 함유 지방유제 | |
JPH0881360A (ja) | 安定な脂肪乳剤 | |
JP5591603B2 (ja) | プロポフォール含有水中油型エマルション組成物 | |
WO2005065676A1 (ja) | パクリタキセルまたはドセタキセルを含む脂肪乳剤 | |
KR20210071901A (ko) | 혼합 세라마이드를 포함하는 화장료 조성물 제조방법 및 상기 방법에 의해 제조한 화장료 조성물 | |
JPH01113315A (ja) | ビタミンk↓2含有脂肪乳剤 | |
JP3611130B2 (ja) | 脂肪乳剤の調製方法 | |
JPS59161313A (ja) | 制癌剤を含有するエマルジヨン製剤 | |
JP2024065470A (ja) | エマルジョン、及びその製造方法 | |
JP2012012331A (ja) | プロポフォール含有水中油型エマルション組成物 | |
JPH09124503A (ja) | アミチアマイシン類の注射用の抗菌性組成物 | |
JPS59141518A (ja) | プロスタグランジン脂肪乳剤 | |
JPH04108732A (ja) | Paf拮抗剤含有脂肪乳剤 | |
JP2001151702A (ja) | リン脂質親和性薬物を含有する非経口薬剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680011878.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11910419 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007521182 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077025488 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006731397 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006731397 Country of ref document: EP |